Daiichi Sankyo’s Covid-19 vaccine trial meets primary endpoint
Japan
Kyowa Kirin and MEI Pharma report data from Phase II lymphoma trial
According to the findings, the ORR following zandelisib treatment was 75.4%.
Positive Phase III lecanemab data for contested Alzheimer’s disease target
Hutchmed’s Phase III colorectal cancer trial meets primary endpoint
Otsuka, Lundbeck report positive data from Phase III Alzheimer’s trial
Daiichi Sankyo Phase III quizartinib trial reports positive AML data
AstraZeneca doses first subjects in Phase III lupus nephritis trial
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
